| 陈俊青,蓝 天,韩 娜.贝伐单抗与重组人血管内皮抑素对人乳腺癌MCF-7细胞裸鼠移植瘤生长的影响[J].中国肿瘤,2014,23(5):408-411. |
| 贝伐单抗与重组人血管内皮抑素对人乳腺癌MCF-7细胞裸鼠移植瘤生长的影响 |
| Effects of Bevacizumab and Recombinant Human Endostatin on Human Breast Cancer MCF-7 Xenografts in Nude Mice |
| 投稿时间：2014-02-03 |
| DOI：10.11735/j.issn.1004-0242.2014.05.A013 |
|
 |
| 中文关键词: 贝伐单抗 重组人血管内皮抑素 乳腺癌 裸鼠移植瘤 |
| 英文关键词:bevacizumab recombinant human endostatin breast cancer nude mice xenografts |
| 基金项目:浙江省医药卫生科学研究基金计划（2010KYB020） |
|
| 摘要点击次数: 1949 |
| 全文下载次数: 959 |
| 中文摘要: |
| 摘 要：［目的］ 探讨贝伐单抗、重组人血管内皮抑素对人乳腺癌MCF-7细胞裸鼠移植瘤生长的影响。［方法］ 建立人乳腺癌裸鼠移植瘤模型，随机分为对照组、低剂量贝伐单抗组、高剂量贝伐单抗组、低剂量重组人血管内皮抑素组、高剂量重组人血管内皮抑素组、低剂量联合组以及高剂量联合组，用药3周。检测裸鼠体重、移植瘤体积、移植瘤重量，计算抑瘤率。［结果］ 与对照组相比，低剂量贝伐单抗组、高剂量贝伐单抗组、低剂量联合组、高剂量联合组裸鼠移植瘤生长曲线较平缓，移植瘤重量明显下降（P＜0.01），抑瘤率分别为67.69％、68.88％、78.32％和79.26％。低剂量联合组与低剂量贝伐单抗组移植瘤重量存在统计学差异（P＜0.05）。低剂量重组人血管内皮抑素组、高剂量重组人血管内皮抑素组移植瘤生长与对照组无统计学差异（P＞0.05）。［结论］ 贝伐单抗能抑制人乳腺癌MCF-7细胞裸鼠移植瘤生长，低剂量贝伐单抗联合重组人血管内皮抑素能进一步提高抗肿瘤作用。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the effects of bevacizumab and recombinant human endostatin (rhES) on the tumor growth of human breast cancer MCF-7 xenografts in nude mice. ［Methods］ Human breast cancer xenografts were established from MCF-7 cells，and nude mice were randomly divided into control group，low-dose bevacizumab group，high-dose bevacizumab group，low-dose rhES group，high-dose rhES group，low-dose combination group and high-dose combination group. The body weight of nude mice，tumor volume and tumor weight were measured. The tumor inhibition rate was evaluated. ［Results］ Tumor weight was significantly decreased in low-dose bevacizumab group，high-dose bevacizumab group，low-dose combination group and high-dose combination group as compared with control (P＜0.01). The tumor growth inhibition rates in low-dose bevacizumab group，high-dose bevacizumab group，low-dose combination group and high-dose combination group were 67.69％，68.88％，78.32％ and 79.26％，respectively. Significant difference in tumor weight between low-dose combination group and low-dose bevacizumab group was observed(P＜0.05). There was no significant difference of tumor growth between rhES group and control group (P＞0.05). ［Conclusion］ Bevacizumab has an inhibitory effect on tumor growth of human breast cancer MCF-7 xenografts，and low-dose bevacizumab combined with rhES may enhance the antitumor activity. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |